

Corporate Medical Policy: Place of Service for Medical Infusions

Related Corporate Medical Policies with Applicable Restricted Product(s):

- Abatacept (Orencia®)
- ADAMTS13, recombinant-krhn (Adzynma®)
- Alpha 1-Antitrypsin Inhibitor Therapy
- Anifrolumab-fnia (Saphnelo™)
- Belimumab (Benlysta®)
- Beremagene geperpavec-svdt (Vyjuvek™)
- Burosumab-twza (Crysvita®)
- Canakinumab (Ilaris®)
- Certolizumab pegol (Cimzia®)
- Crizanlizumab-tmca (Adakveo®)
- Crovalimab-akkz (PiaSky™)
- Eculizumab (Soliris®)
- Edaravone (Radicava®)
- Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders
- Eptinezumab-jjmr (Vyepi™)
- Evinacumab-dgnb (Evkeeza™)
- Fosdenopterin (Nulibry™)
- Givosiran (Givlaari®)
- Golimumab (Simponi Aria®)
- Guselkumab (Tremfya®)
- Ibalizumab-uiyk (Trogarzo®)
- Imetelstat (Rytelo™)
- Immunoglobulin Therapy
- Inclisiran (Leqvio®)
- Inebilizumab-cdon (Uplizna™)
- Infliximab (Remicade®) and Infliximab Biosimilars
- Interleukin-5 Antagonists

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

- Letermovir (Prevymis™)
- Lumasiran (Oxlumo™)
- Luspatercept-aamt (Reblozyl®)
- Natalizumab (Tysabri®) and Natalizumab Biosimilars
- Nedosiran (Rivfloza™)
- Ocrelizumab (Ocrevus®, Ocrevus Zunovo™)
- Omalizumab (Xolair®)
- Patisiran (Onpattro®)
- Pegcetacoplan (Empaveli™)
- Plasminogen, human-tvmh (Ryplazim®)
- Pozelimab-bbfg (Veopoz™)
- Ravulizumab-cwvz (Ultomiris®)
- Romiplostim (NPlate®)
- Romosozumab-aqqg (Evenity™)
- Secukinumab (Cosentyx®)
- Somatostatin Analogs
- Sutimlimab (Enjaymo™)
- Teprotumumab-trbw (Tepezza™)
- Tezepelumab-ekko (Tezspire™)
- Tildrakizumab-asmn (Ilumya®)
- Tocilizumab (Actemra®) and Tocilizumab Biosimilars
- Treatment of Hereditary Angioedema
- Ublituximab-xiiy (Briumvi™)
- Ustekinumab (Stelara®)
- Vedolizumab (Entyvio®)
- Vutrisiran (Amvuttra™)

**NOTE: A comprehensive list of the individual restricted products that are applicable to this policy is included below in the “Restricted Product(s) Applicable to Policy” table.

Other Related Corporate Medical Policies:

- Infusion Therapy in the Home
- Private Duty Nursing Services

Rationale:

- Inpatient hospital and outpatient facilities are uniquely equipped to handle and support emergency medical situations. It is appropriate for patients, who are medically unstable and in danger of needing medical services only available in an outpatient hospital setting, to have access to medical injections or infusions in these facilities.
- For those patients who are considered medically stable, drug injections or infusions may be administered in settings that would be considered less intensive, yet safe and effective alternatives. Acceptable alternative sites of care include non-hospital outpatient centers, physician/professional offices, infusion suites/ambulatory infusion centers, and infusions administered at home.
- Alternative places of service may be more convenient for the patient, less expensive, and lessen risk of exposure to hospital acquired infections.
- Guidelines and agencies support first injections or infusions of most drugs in well-controlled, hospital-based settings. This is to ensure emergency access to care to address serious infusion-associated adverse reactions, such as anaphylaxis or severe hypotension. Research has shown the safety and efficacy of administering subsequent injections or infusions in a less intensive environment, including the home setting.
- **Please note, this policy specifically applies to the injection or infusion drugs that are addressed separately in individual medical policies as referenced above in the “Restricted Product(s)” section.

Criteria for Medical Necessity:

Medical injection or infusion therapy of the restricted product(s) in an inpatient or outpatient hospital setting is considered medically necessary when the following criteria are met:

1. For requests for injection or infusion administration in an **inpatient setting**, the injection or infusion may be given if the inpatient admission is NOT for the sole purpose of administering the injection or infusion; **OR**
2. For requests for injection or infusion administration in an **outpatient hospital setting**, the injection or infusion may be given if ONE of the following criteria are met:

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

- a. History of a severe adverse event following that injection or infusion (i.e., anaphylaxis, seizure, thromboembolism, myocardial infarction, renal failure); **OR**
 - b. Conditions that cause an increased risk for severe adverse event (i.e., unstable renal function, cardiopulmonary conditions, unstable vascular access); **OR**
 - c. History of mild adverse events that have not been successfully managed through mild pre-medication (e.g., diphenhydramine, acetaminophen, steroids, fluids, etc.); **OR**
 - d. Inability to physically and cognitively adhere to the treatment schedule and regimen complexity; **OR**
 - e. New to therapy, defined as initial injection or infusion OR less than 3 months since initial injection or infusion; **OR**
 - f. Re-initiation of therapy, defined as ONE of the following:
 - i. First injection or infusion after 6 months of no injections or infusions for drugs with an approved dosing interval less than 6 months duration; **OR**
 - ii. First injection or infusion after at least a 1-month gap in therapy outside of the approved dosing interval for drugs requiring every 6 months dosing duration; **OR**
 - g. Requirement of a change in the requested restricted product formulation; **AND**
3. If the Site of Care Medical Necessity Criteria in #1 or #2 above are not met, the injection or infusion will be administered in a **home-based infusion** or physician office setting with or without supervision by a certified healthcare professional.

| Restricted Product(s) Applicable to Policy | | |
|--------------------------------------------|----------------------------------------------------------------------------------|-------|
| Related Corporate Medical Policy | Medication | HCPCS |
| Abatacept (Orencia®) | abatacept (Orencia®) intravenous (IV) infusion or subcutaneous (SC) injection | J0129 |
| ADAMTS13, recombinant-krhn (Adzynma®) | ADAMTS13, recombinant-krhn (Adzynma®) intravenous (IV) infusion | J7171 |

| Restricted Product(s) Applicable to Policy | | |
|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|--------------|
| Related Corporate Medical Policy | Medication | HCPCS |
| Alpha 1-Antitrypsin Inhibitor Therapy | alpha 1-proteinase inhibitor (human) (Aralast NP™) intravenous (IV) infusion | J0256 |
| | alpha 1-proteinase inhibitor (human) (Glassia®) intravenous (IV) infusion | J0257 |
| | alpha 1-proteinase inhibitor (human) (Prolastin®-C) intravenous (IV) infusion | J0256 |
| | alpha 1-proteinase inhibitor (human) (Zemaira®) intravenous (IV) infusion | J0256 |
| Anifrolumab-fnia (Saphnelo™) | anifrolumab-fnia (Saphnelo™) intravenous (IV) infusion | J0491 |
| Belimumab (Benlysta®) | belimumab (Benlysta®) intravenous (IV) infusion or subcutaneous (SC) injection | J0490 |
| Beremagene geperpavec-svdt (Vyjuvek™) | Beremagene geperpavec-svdt (Vyjuvek™) biological suspension mixed with excipient gel for topical application | J3401 |
| Burosumab-twza (Crysvita®) | burosumab-twza (Crysvita®) subcutaneous (SC) injection | J0584 |

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

| Restricted Product(s) Applicable to Policy | | |
|---------------------------------------------------|---------------------------------------------------------------------------------------|----------------------------|
| Related Corporate Medical Policy | Medication | HCPGS |
| Canakinumab (Ilaris®) | canakinumab (Ilaris®) subcutaneous (SC) injection | J0638 |
| Certolizumab pegol (Cimzia®) | certolizumab pegol (Cimzia®) subcutaneous (SC) injection | J0717 |
| Crizanlizumab-tmca (Adakveo®) | crizanlizumab-tmca (Adakveo®) intravenous (IV) infusion | J0791 |
| Crovalimab-akkz (PiaSky™) | crovalimab-akkz (PiaSky™) intravenous (IV) infusion or subcutaneous (SC) injection | C9399* J3490* J3590* |
| Eculizumab (Soliris®) | eculizumab (Soliris®) intravenous (IV) infusion | J1300 |
| | eculizumab-aeab (Bkemv™) intravenous (IV) infusion | C9399* J3490* J3590* |
| | eculizumab-aagh (Epysqli®) intravenous (IV) infusion | C9399* J3490* J3590* |
| Edaravone (Radicava®) | edaravone (Radicava®) intravenous (IV) infusion | J1301 |

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

| Restricted Product(s) Applicable to Policy | | |
|------------------------------------------------------------------|--------------------------------------------------------------------|--------------|
| Related Corporate Medical Policy | Medication | HCPCS |
| Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders | laronidase (Aldurazyme®) intravenous (IV) infusion | J1931 |
| | imiglucerase (Cerezyme®) intravenous (IV) infusion | J1786 |
| | idursulfase (Elaprase®) intravenous (IV) infusion | J1743 |
| | taliglucerase alfa (Elelyso®) intravenous (IV) infusion | J3060 |
| | pegunigalsidase alfa-iwxj (Elfabrio®) intravenous (IV) infusion | J2508 |
| | agalsidase beta (Fabrazyme®) intravenous (IV) infusion | J0180 |
| | sebelipase alfa (Kanuma®) intravenous (IV) infusion | J2840 |
| | velmanase alfa-tycv (Lamzed®) intravenous (IV) infusion | J0217 |

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

| Restricted Product(s) Applicable to Policy | | |
|---------------------------------------------------|----------------------------------------------------------------------|--------------|
| Related Corporate Medical Policy | Medication | HCPCS |
| | alglucosidase alfa (Lumizyme®) intravenous (IV) infusion | J0221 |
| | vestronidase alfa-vjvk (Mepsevii™) intravenous (IV) infusion | J3397 |
| | galsulfase (Naglazyme®) intravenous (IV) infusion | J1458 |
| | avalglucosidase alfa-ngpt (Nexviazyme™) intravenous (IV) infusion | J0219 |
| | cipaglucosidase alfa-atga (Pombiliti™) intravenous (IV) infusion | J1203 |
| | elosulfase alfa (Vimizim®) intravenous (IV) infusion | J1322 |
| | velaglucerase alfa (Vpriv®) intravenous (IV) infusion | J3385 |
| | olipudase alfa-rpcp (Xenpozyme™) intravenous (IV) infusion | J0218 |

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

| Restricted Product(s) Applicable to Policy | | |
|---------------------------------------------------|----------------------------------------------------------|--------------------------------------|
| Related Corporate Medical Policy | Medication | HCPs |
| Eptinezumab-jjmr (Vyepi™) | eptinezumab-jjmr (Vyepi™) intravenous (IV) infusion | J3032 |
| Evinacumab-dgnb (Evkeeza™) | evinacumab-dgnb (Evkeeza™) intravenous (IV) infusion | J1305 |
| Fosdenopterin (Nulibry™) | fosdenopterin (Nulibry™) intravenous (IV) infusion | C9399* J3490* J3590* |
| Givosiran (Givlaari®) | givosiran (Givlaari®) subcutaneous (SC) injection | J0223 |
| Golimumab (Simponi Aria®) | golimumab (Simponi Aria®) intravenous (IV) infusion | J1602 |
| Guselkumab (Tremfya®) | guselkumab (Tremfya®) subcutaneous (SC) injection | J1628 |
| Ibalizumab-uiyk (Trogarzo®) | ibalizumab-uiyk (Trogarzo®) intravenous (IV) infusion | J1746 |
| Imetelstat (Rytelo™) | imetelstat (Rytelo™) intravenous (IV) infusion | C9399* J3490* J3590* J9999* |

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

| Restricted Product(s) Applicable to Policy | | |
|--------------------------------------------|----------------------------------------------------|----------------------------------------------|
| Related Corporate Medical Policy | Medication | HCPCS |
| Immunoglobulin Therapy | Alyglo™ intravenous (IV) immune globulin | C9399* J3490* J3590* J1599 90283 |
| | Asceniv™ intravenous (IV) immune globulin | J1554 90283 |
| | Bivigam® intravenous (IV) immune globulin | J1556 90283 |
| | Cutaquig® subcutaneous (SC) immune globulin | J1551 90284 |
| | Cuvitru™ subcutaneous (SC) immune globulin | J1555 90284 |
| | Flebogamma® intravenous (IV) immune globulin | J1572 90283 |
| | Gammagard S/D® intravenous (IV) immune globulin | J1566 90283 |

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

| Restricted Product(s) Applicable to Policy | | |
|---------------------------------------------------|----------------------------------------------------------------------------|-------------------------|
| Related Corporate Medical Policy | Medication | HCPCS |
| | Gammagard™ Liquid intravenous (IV) or subcutaneous (SC) immune globulin | J1569 90283 90284 |
| | Gammaked™ intravenous (IV) or subcutaneous (SC) immune globulin | J1561 90283 90284 |
| | Gammaplex® intravenous (IV) immune globulin | J1557 90283 |
| | Gamunex-C® intravenous (IV) or subcutaneous (SC) immune globulin | J1561 90283 90284 |
| | Hizentra® subcutaneous (SC) immune globulin | J1559 90284 |
| | HyQvia™ subcutaneous (SC) immune globulin | J1575 90284 |
| | Octagam® intravenous (IV) immune globulin | J1568 90283 |
| | Panzyga® intravenous (IV) immune globulin | J1576 90283 |

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

| Restricted Product(s) Applicable to Policy | | |
|---------------------------------------------------|-------------------------------------------------------------------|-------------------------------------|
| Related Corporate Medical Policy | Medication | HCPGS |
| | Privigen® intravenous (IV) immune globulin | J1459 90283 |
| | Xembify™ subcutaneous (SC) immune globulin | J1558 90284 |
| | Yimmugo® intravenous (IV) immune globulin | C9399* J3490* J3590* 90283 |
| Inclisiran (Leqvio®) | inclisiran (Leqvio®) subcutaneous (SC) injection | J1306 |
| Inebilizumab-cdon (Uplizna™) | inebilizumab-cdon (Uplizna™) intravenous (IV) infusion | J1823 |
| Infliximab (Remicade®) and Infliximab Biosimilars | infliximab (Remicade®) or Infliximab intravenous (IV) infusion | J1745 |
| | infliximab-axxq (Avsola™) intravenous (IV) infusion | Q5121 |

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

| Restricted Product(s) Applicable to Policy | | |
|--------------------------------------------|--------------------------------------------------------------|----------------------------|
| Related Corporate Medical Policy | Medication | HCPCS |
| | infliximab-dyyb (Inflectra®) intravenous (IV) infusion | Q5103 |
| | infliximab-abda (Renflexis®) intravenous (IV) infusion | Q5104 |
| Interleukin-5 Antagonists | reslizumab (Cinqair®) intravenous (IV) infusion | J2786 |
| | benralizumab (Fasenra®) subcutaneous (SC) injection | J0517 |
| | mepolizumab (Nucala®) subcutaneous (SC) injection | J2182 |
| Letermovir (Prevymis™) | letermovir (Prevymis™) intravenous (IV) infusion | C9399* J3490* J3590* |
| Lumasiran (Oxlumo™) | lumasiran (Oxlumo™) subcutaneous (SC) injection | J0224 |
| Luspatercept-aamt (Reblozyl®) | luspatercept-aamt (Reblozyl®) subcutaneous (SC) injection | J0896 |

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

| Restricted Product(s) Applicable to Policy | | |
|----------------------------------------------------|-------------------------------------------------------------------------------------|----------------------------|
| Related Corporate Medical Policy | Medication | HCPs |
| Natalizumab (Tysabri®) and Natalizumab Biosimilars | natalizumab (Tysabri®) intravenous (IV) infusion | J2323 |
| | natalizumab-sztn (Tyruko®) intravenous (IV) infusion | Q5134 |
| Nedosiran (Rivfloza™) | nedosiran (Rivfloza™) subcutaneous (SC) injection | C9399* J3490* J3590* |
| Ocrelizumab (Ocrevus®, Ocrevus Zunovo™) | ocrelizumab (Ocrevus®) intravenous (IV) infusion | J2350 |
| | ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo™) subcutaneous (SC) injection | C9399* J3490* J3590* |
| Omalizumab (Xolair®) | omalizumab (Xolair®) subcutaneous (SC) injection | J2357 |
| Patisiran (Onpattro®) | patisiran (Onpattro®) intravenous (IV) infusion | J0222 |
| Pegcetacoplan (Empaveli™) | pegcetacoplan (Empaveli™) subcutaneous (SC) infusion | C9399* J3490* J3590* |

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

| Restricted Product(s) Applicable to Policy | | |
|---------------------------------------------------|---------------------------------------------------------------------------------------|--------------|
| Related Corporate Medical Policy | Medication | HCPCS |
| Plasminogen, human-tvmh (Ryplazim®) | plasminogen, human-tvmh (Ryplazim®) intravenous (IV) infusion | J2998 |
| Pozelimab-bbfg (Veopoz™) | pozelimab-bbfg (Veopoz™) intravenous (IV) infusion or subcutaneous (SC) injection | J9376 |
| Ravulizumab-cwvz (Ultomiris®) | ravulizumab-cwvz (Ultomiris®) intravenous (IV) infusion | J1303 |
| Romiplostim (NPlate®) | romiplostim (NPlate®) subcutaneous (SC) injection | J2796 |
| Romozosumab-aqqg (Evenity™) | romozosumab-aqqg (Evenity™) subcutaneous (SC) injection | J3111 |
| Secukinumab (Cosentyx®) | secukinumab (Cosentyx®) intravenous (IV) infusion | J3247 |
| Somatostatin Analogs | octreotide (Sandostatin®) intravenous (IV) infusion or subcutaneous (SC) injection | J2354 |
| | octreotide (Sandostatin® LAR Depot) gluteal intramuscular (IM) injection | J2353 |

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

| Restricted Product(s) Applicable to Policy | | |
|-----------------------------------------------------------------|-------------------------------------------------------------------------------------------------|----------------|
| Related Corporate Medical Policy | Medication | HCP/PCS |
| | pasireotide (Signifor [®] LAR) intramuscular (IM) injection | J2502 |
| | lanreotide (Somatuline [®] Depot) subcutaneous (SC) injection | J1930 J1932 |
| Sutimlimab (Enjaymo [™]) | sutimlimab (Enjaymo [™]) intravenous (IV) infusion | J1302 |
| Teprotumumab-trbw (Tepezza [™]) | teprotumumab-trbw (Tepezza [™]) intravenous (IV) infusion | J3241 |
| Tezepelumab-ekko (Tezspire [™]) | tezepelumab-ekko (Tezspire [™]) subcutaneous (SC) injection | J2356 |
| Tildrakizumab-asmn (Ilumya [®]) | tildrakizumab-asmn (Ilumya [®]) subcutaneous (SC) injection | J3245 |
| Tocilizumab (Actemra [®]) and Tocilizumab Biosimilars | tocilizumab (Actemra [®]) intravenous (IV) infusion or subcutaneous (SC) injection | J3262 |
| | tocilizumab-bavi (Tofidence [™]) intravenous (IV) infusion | Q5133 |

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

| Restricted Product(s) Applicable to Policy | | |
|---------------------------------------------------|----------------------------------------------------------------------------------------|--------------|
| Related Corporate Medical Policy | Medication | HCPCS |
| | tocilizumab-aazg (Tyenne®) intravenous (IV) infusion or subcutaneous (SC) injection | Q5135 |
| Treatment of Hereditary Angioedema | C1 esterase inhibitor (Berinert®) intravenous (IV) injection | J0597 |
| | C1 esterase inhibitor (Cinryze®) intravenous (IV) injection | J0598 |
| | icatibant (Firazyr®) subcutaneous (SC) injection | J1744 |
| | ecallantide (Kalbitor®) subcutaneous (SC) injection | J1290 |
| | C1 esterase inhibitor (Ruconest®) intravenous (IV) injection | J0596 |
| Ublituximab-xiiy (Briumvi™) | ublituximab-xiiy (Briumvi™) intravenous (IV) infusion | J2329 |

| Restricted Product(s) Applicable to Policy | | |
|--------------------------------------------|------------------------------------------------------------------------------------------|----------------------------|
| Related Corporate Medical Policy | Medication | HCPCS |
| Ustekinumab (Stelara®) | ustekinumab (Stelara®) intravenous (IV) infusion or subcutaneous (SC) injection | J3357 J3358 |
| | ustekinumab-aauz (Otulfi™) intravenous (IV) infusion or subcutaneous (SC) injection | C9399* J3490* J3590* |
| | ustekinumab-ttwe (Pyzchiva®) intravenous (IV) infusion or subcutaneous (SC) injection | C9399* J3490* J3590* |
| | ustekinumab-aekn (Selarsdi™) subcutaneous (SC) injection | C9399* J3490* J3590* |
| | ustekinumab-auub (Wezlana™) intravenous (IV) infusion or subcutaneous (SC) injection | Q5137 Q5138 |
| Vedolizumab (Entyvio®) | vedolizumab (Entyvio®) intravenous (IV) infusion | J3380 |
| Vutrisiran (Amvuttra™) | vutrisiran (Amvuttra™) subcutaneous (SC) injection | J0225 |

***Non-specific assigned HCPCS codes, please refer to product NDC**

Other service codes that may be applicable: 86711, 99506, 99601, 99602, S0353, S0354, S5035, S5036, S5497, S5498, S5501, S5502, S5517, S5518, S5520, S5521, S5522, S5523, S9123, S9124, S9208, S9325, S9326, S9327, S9328, S9329, S9330, S9331, S9336, S9338, S9345, S9346,

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

S9347, S9348, S9349, S9351, S9353, S9355, S9357, S9359, S9361, S9363, S9364, S9365, S9366, S9367, S9368, S9370, S9372, S9373, S9374, S9375, S9376, S9377, S9379, S9490, S9494, S9497, S9500, S9501, S9502, S9503, S9504, S9537, S9538, S9542, S9558, S9559, S9810, E0691-E0694, G0138

NOTE:

- Charges for routinely included supplies such as gauze, infusion sets, needles, cassettes, tape, cleansing solutions (e.g., betadine, alcohol), heparin and saline flushes, diluents for mixing drugs, and splints are included in the infusion reimbursement.
- Catheter care may be reported separately when used as a stand-alone therapy, or during days not covered under per diem by another therapy. PICC line care will only be allowed as a separate charge if there is no other therapy in the last 30 days in the home.
- Home infusion therapy includes all of the components related to such therapy, such as, but not limited to, nursing services, durable medical equipment, supplies, Prescription and non-Prescription Legend Drugs and solutions, pharmacy compounding and dispensing, specimen collection, patient and family education, delivery of drugs and supplies, and management of emergencies arising from said therapy.

References: all information referenced is from FDA package insert unless otherwise noted below.

Policy Implementation/Update Information: Criteria and treatment protocols are reviewed annually by the Blue Cross NC P&T Committee, regardless of change. This policy is reviewed in Q4 annually.

October 2024: Criteria update: Additions made throughout policy for clarity to align with each applicable individual medical policy – Added crovalimab-akkz (PiaSky), imetelstat (Rytelo), and intravenous immune globulin (Yimmugo). Added ocrelizumab/hyaluronidase-ocsq (Ocrevus Zunovo) and changed policy name to Ocrelizumab (Ocrevus, Ocrevus Zunovo). Added Actemra biosimilars [tocilizumab-bavi (Tofidence) and tocilizumab-aazg (Tyenne)] and changed policy name to Tocilizumab (Actemra) and Tocilizumab Biosimilars. Added Soliris biosimilars [eculizumab-aeab (Bkemv) and eculizumab-aagh (Epysqli)]. Added Stelara biosimilars [ustekinumab-aaaz (Otulfi), ustekinumab-ttwe (Pyzchiva), ustekinumab-aeakn (Selarsdi), ustekinumab-auub (Wezlana)].

October 2024: Coding update: Coding updates made throughout policy for clarity to align with standard quarterly coding updates located within each applicable individual medical policy – Added HCPCS code J7171 for Adzynma effective 7/1/2024 and deleted codes C9399/C9167, J3490, J3590 termed 6/30/2024. Added HCPCS code J1203 for Pombiliti effective 4/1/2024 and deleted codes C9399, J3490, J3590 termed 3/31/2024. Added HCPCS code G0138 for Pombiliti as an additional code that may be applicable effective 4/1/2024. For Alyglo within Immunoglobulin Therapy policy, added codes J1599 (non-specified intravenous immune globulin) and 90283, and removed code J1599 from Panzyga for clarity. Added HCPCS code Q5134 for Tyruko effective 4/1/2024 and deleted codes C9399, J3490, J3590 termed 3/31/2024. Added HCPCS code J9376 for Veopoz effective 4/1/2024 and deleted codes C9399, J3490, J3590 termed 3/31/2024. Added HCPCS code J3247 for Cosentyx IV effective 7/1/2024 and deleted codes C9399/C9166, J3490, J3590 termed 6/30/2024.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

February 2024: Criteria update: Added ADAMTS13 recombinant-krhn (Adzynma), intravenous immune globulin (Alyglo), secukinumab (Cosentyx IV), cipaglifosidase alfa-atga (Pombiliti), nedosiran (Rivfloza), natalizumab-sztn (Tyruko), pozelimab-bbfg (Veopoz) to policy with HCPCS codes C9399, J3490, and J3590. For Vyjuvek, added HCPCS code J3401 to dosing reference table effective 1/1/2024; deleted C9399, J3490, and J3590 termed 12/31/2023. Added HCPCS code J0217 for Lamzede to dosing reference table effective 1/1/2024; deleted C9399, J3490, J3590 termed 12/31/2023. Added HCPCS code J2508 for Elfabrio to dosing reference table effective 1/1/2024; deleted C9399, J3490, J3590 termed 12/31/2023.

August 2023: Criteria update: Added pegunigalsidase alfa-iwxj (Elfabrio) and velmanase alfa-tycv (Lamzede) to policy with HCPCS codes C9399, J3490, and J3590. Added beremagene geperpavec-svdt (Vyjuvek) to policy with HCPCS codes C9399, J3490, and J3590. Added non-branded Infliximab for clarity with associated HCPCS code for Remicade (J1745).

August 2023: Coding change: For IVIG products: Added HCPCS code J1576 for Panzyga effective 7/1/2023; removed J1599 from Asceniv, Bivigam, Flebogamma, Gammagard Liquid, Gammaked, Gammplex, Gamunex-C, Octagam, and Privigen for clarity according to coding definition; removed J1599 and J1569 from Gammagard S/D for clarity according to coding definition; removed Carimune NF from policy due to product discontinuation. For Briumvi, added HCPCS code J2329 to restricted product table effective 7/1/2023, deleted C9399, J3490, and J3590 termed 6/30/2023.

April 2023: Coding update: For Xenpozyme, added HCPCS code J0218 to restricted product table effective 4/1/2023, deleted C9399, J3490, and J3590 termed 3/31/2023.

April 2023: Criteria update: Added ublituximab-xiyy (Briumvi) to policy with HCPCS codes C9399, J3490, and J3590.

January 2023: Coding update: For Amvuttra, added HCPCS code J0225 to restricted product table effective 1/1/2023, deleted C9399, J3490, and J3590 termed 12/31/2022.

October 2022: Criteria update: Added enzyme replacement therapy, olipudase alfa-rpcp (Xenpozyme) to policy with HCPCS codes C9399, J3490, and J3590. Updated codes for multiple drugs: For Enjaymo, added HCPCS code J1302, deleted C9094, J3490, J3590; for lanreotide (Somatuline Depot), added HCPCS J1932.

August 2022: Criteria update: Added vutrisiran (Amvuttra) to policy with HCPCS codes C9399, J3490, and J3590. Updated codes for multiple drugs: For Saphnelo, added HCPCS code J0491 effective 4/1/22, deleted C9086, J3490, J3590; for Nexviazyme, added HCPCS code J0219 effective 4/1/2022, deleted C9085, J3490, J3590; for Cutaquig, added HCPCS code J1551 effective 7/1/2022, deleted C9399, J3490, and J3590 termed 6/30/2022; for Leqvio, added HCPCS code J1306 effective 7/1/2022, deleted C9399, J3490, and J3590 termed 6/30/2022; for Ryplazim, added HCPCS code J2998 effective 7/1/2022, deleted C9399, J3490, and J3590 termed 6/30/2022; for Enjaymo, added HCPCS code C9094 effective 7/1/2022, deleted C9399 termed 6/30/2022; for Tezspire, added HCPCS code J2356 effective 7/1/2022, deleted C9399, J3490, and J3590 termed 6/30/2022.

February 2022: Criteria update: Added the following drugs and HCPCS codes for clarity, with criteria also available in individual policies: Nexviazyme (C9085, J3490, J3590), Saphnelo (C9086, J3490, J3590), Tezspire (C9399, J3490, J3590), Enjaymo (C9399**, J3490**, J3590**), and Leqvio (C9399, J3490, J3590). Updated HCPCS code for Evkeeza to J1305.

October 2021: Criteria change: Expanded policy to include the following restricted products: Benlysta, Crysvida, Ilaris, Cimzia, Adakveo, Vyepti, Evkeeza, Nulibry, Givlaari, Tremfya, Trogarzo, Uplizna, Prevymis, Oxlumo, Reblozyl, Onpattro, Ryplazim, Empaveli, NPlate, Evenity, Somatostatin Analogs, Tepezza, Ilumya, Stelara; added associated HCPCS/CPT codes: J0490, J0584, J0638, J0717, J0791, J3032, C9079, C9399, J3490, J3590, J0223, J1628, J1746, J1823, J0224, J0896, J0222, J2796, J3111, J2354, J2353, J2502, J1930, J3241, J3245, J3357, J3358. Corrected restricted products and codes for clarity to include: Asceniv, Fasenra, Radicava, and Ultomiris with associated codes J1554, J0517, J1301, and J1303; medical policy formatting change. **Policy notification given 8/2/2021 for effective date 10/1/2021.**

*Further historical criteria changes and updates available upon request from Medical Policy and/or Corporate Pharmacy.